A Phase 2, Single-Blind, Randomized Study of Safety and Immunogenicity Following Vaccination With Single or Double Doses of HEPLISAV in Adults With End-Stage Renal Disease

Trial Profile

A Phase 2, Single-Blind, Randomized Study of Safety and Immunogenicity Following Vaccination With Single or Double Doses of HEPLISAV in Adults With End-Stage Renal Disease

Discontinued
Phase of Trial: Phase II

Latest Information Update: 06 Mar 2017

At a glance

  • Drugs V 270 (Primary)
  • Indications Hepatitis B
  • Focus Pharmacodynamics
  • Sponsors Dynavax Technologies
  • Most Recent Events

    • 14 Apr 2010 Results presented in a poster session at the National Kidney Foundation Spring Clinical Meeting, as reported by Dynavax Technologies.
    • 21 Apr 2008 Added Dynavax Technologies as a sponsor (from ClinicalTrials.gov).
    • 21 Apr 2008 Status changed from suspended to discontinued. According to ClinicalTrials.gov, this study is on clinical hold.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top